<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Chemokines and their receptors play key roles in leukocyte trafficking and are also implicated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We previously demonstrated that forced expression of CXCR3 promotes <z:hpo ids='HP_0003003'>colon cancer</z:hpo> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> preferentially to the draining lymph nodes (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LNs</z:e>), with poor prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>Using clinical <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) samples, here, we show that expressions of CXCR3 and CXCR4 are significantly higher in metastatic foci within <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LNs</z:e> and liver compared to <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, whereas ligands for CXCR3 and CXCR4 are not </plain></SENT>
<SENT sid="3" pm="."><plain>We also have demonstrated that some human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines constitutively express both CXCR3 and CXCR4, and that activation of CXCR3 strengthens the CXCR4-mediated cell migration in vitro in a synergistic manner </plain></SENT>
<SENT sid="4" pm="."><plain>By constructing SW620 cell lines with reduced expression of CXCR3 and/or CXCR4 using microRNA, we investigated in vivo metastatic activities in a mouse rectal transplantation model </plain></SENT>
<SENT sid="5" pm="."><plain>Six weeks after inoculation, CXCR3-, CXCR4-, and CXCR3/CXCR4 double-knockdowns significantly reduced <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LNs</z:e>, liver and lungs, compared to the control (p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Importantly, its suppressive effect on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> was significantly stronger in CXCR3- and CXCR3/CXCR4 double-knockdowns </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, CXCR3- and CXCR3/CXCR4 double-knockdowns significantly decreased the dissemination of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells to liver and lungs, even after 2 weeks </plain></SENT>
<SENT sid="8" pm="."><plain>These results indicate that targeting CXCR3 and CXCR4 can be a promising therapy against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
</text></document>